Literature DB >> 2684709

Type II diabetes, glucose "non-sense," and islet desensitization.

R P Robertson1.   

Abstract

A universal finding in hyperglycemic patients with type II (non-insulin-dependent) diabetes mellitus is that all share a common defect in glucose recognition resulting in abnormal insulin secretion by pancreatic islet beta-cells. This defect is 1) specific for glucose signals rather than global, 2) related to chronic hyperglycemia, and 3) partially reversible after brief treatment with insulin to induce normoglycemia and through use of other pharmacological agents without normalizing glucose levels. My perspective is that an essential component of this defect is secondary and may represent a state of homologous desensitization of the beta-cell secretory apparatus to glucose. Elucidation of the biochemical mechanism(s) of defective recognition of glucose signals by beta-cells--or glucose "non-sense"--in these patients will provide key insights into the pathogenesis of type II diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684709     DOI: 10.2337/diab.38.12.1501

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  23 in total

1.  Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.

Authors:  R P Robertson; H J Zhang; K L Pyzdrowski; T F Walseth
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 2.  Effects of prolonged glucose stimulation on pancreatic beta cells: from increased sensitivity to desensitization.

Authors:  F Purrello; A M Rabuazzo; M Anello; G Patanè
Journal:  Acta Diabetol       Date:  1996-12       Impact factor: 4.280

3.  Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15.

Authors:  A Moran; H J Zhang; L K Olson; J S Harmon; V Poitout; R P Robertson
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

4.  Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells.

Authors:  T Matsuoka; Y Kajimoto; H Watada; H Kaneto; M Kishimoto; Y Umayahara; Y Fujitani; T Kamada; R Kawamori; Y Yamasaki
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

5.  Chronic exposure of betaTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator.

Authors:  V Poitout; L K Olson; R P Robertson
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

6.  Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein.

Authors:  L K Olson; J B Redmon; H C Towle; R P Robertson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Effect of LDL and serum from diabetic subjects on DNA synthesis in HIT-cells in culture.

Authors:  M I Shoukry; M S el-Khatim; K A Gumaa
Journal:  Acta Diabetol       Date:  1994-04       Impact factor: 4.280

8.  Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy.

Authors:  A D Baron; M Laakso; G Brechtel; S V Edelman
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

9.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

10.  Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients.

Authors:  Y T Kruszynska; D S Harry; R N Bergman; N McIntyre
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.